GMP IPO Watch
Nippon India Pharma Fund
Direct Plan · Growth Option · Nippon India Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.01% | +3.52% | 202 of 255 |
| 1M | +1.64% | +1.97% | 154 of 255 |
| 3M | -0.65% | -3.45% | 50 of 252 |
| 6M | +8.75% | +2.92% | 55 of 251 |
| YTD | +12.15% | +1.21% | 40 of 255 |
| 1Y | +10.54% | +1.11% | 41 of 232 |
| 2Y | +6.27% | +2.39% | 54 of 187 |
| 3Y | +18.85% | +12.36% | 30 of 142 |
| 5Y | +14.53% | +9.81% | 29 of 102 |
| 7Y | +22.03% | +14.27% | 11 of 84 |
| 10Y | +16.06% | +11.68% | 16 of 68 |
| INCEPTION | +17.34% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +4.61% | +50.08% | -14.04% | 67% | 27% |
| 6M | +9.44% | +72.71% | -17.67% | 71% | 30% |
| 1Y | +20.08% | +90.70% | -15.12% | 77% | 34% |
| 2Y | +18.51% | +53.20% | -11.06% | 94% | 42% |
| 3Y | +17.20% | +32.16% | -1.27% | 99% | 45% |
| 5Y | +16.56% | +32.13% | +0.02% | 100% | 45% |
| 7Y | +17.24% | +24.08% | +9.49% | 100% | 46% |
| 10Y | +16.24% | +18.84% | +13.12% | 100% | 46% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity97.31%
- Debt0.00%
- Cash2.69%
- Other0.00%
Market Cap Split
- Large Cap29.71%
- Mid Cap39.02%
- Small Cap28.58%
- Others2.69%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 37.98 | 41.94 |
| P/B | 5.60 | 6.29 |
| Price / Sales | 5.03 | 6.05 |
| Price / Cash Flow | 27.60 | 31.26 |
| Dividend Yield (%) | 0.84 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 11.71% | -0.66% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 7.10% | +0.10% |
| Lupin | Pharmaceuticals & Biotechnology | 6.17% | -0.26% |
| Cipla | Pharmaceuticals & Biotechnology | 6.01% | -0.08% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 5.45% | +0.52% |
| Apollo Hospitals | Equity | 4.89% | -0.26% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 4.38% | +0.29% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 3.92% | -0.02% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 3.61% | +0.14% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.11% | -0.20% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.87% | +0.03% |
| Triparty Repo | Reverse Repo / TREPS | 2.81% | — |
| Max Healthcare Institute | Equity | 2.70% | -0.22% |
| Vijaya Diagnostic Centre | Equity | 2.62% | -0.06% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 2.53% | +0.09% |
View all 39 holdings
| Medplus Health Services | Retailing | 2.53% | +0.02% |
| Abbott | Pharmaceuticals & Biotechnology | 2.32% | +0.19% |
| Thyrocare Technologies | Equity | 2.24% | -0.21% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 2.24% | -0.01% |
| Dr. Lal Path Labs | Equity | 2.17% | +0.13% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 1.82% | +0.00% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 1.65% | +0.02% |
| Narayana Hrudayalaya | Equity | 1.61% | -0.05% |
| Suraksha Diagnostic | Equity | 1.51% | +0.12% |
| Syngene International | Equity | 1.40% | -0.08% |
| Emcure Pharmaceuticals | Pharmaceuticals & Biotechnology | 1.36% | +0.11% |
| Pfizer | Pharmaceuticals & Biotechnology | 1.35% | -0.22% |
| Akums Drugs & Pharma | Pharmaceuticals & Biotechnology | 1.21% | +0.10% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 1.19% | -0.01% |
| Fortis Healthcare | Equity | 1.13% | -0.16% |
| Biocon | Pharmaceuticals & Biotechnology | 1.01% | -0.08% |
| Sanofi | Pharmaceuticals & Biotechnology | 1.00% | +0.01% |
| Sanofi Consumer Healthcare | Pharmaceuticals & Biotechnology | 0.89% | -0.04% |
| Molbio Diagnostics | Equity | 0.54% | +0.10% |
| Indoco Remedies | Pharmaceuticals & Biotechnology | 0.48% | +0.01% |
| AstraZeneca Pharma | Pharmaceuticals & Biotechnology | 0.42% | -0.04% |
| Concord Biotech | Pharmaceuticals & Biotechnology | 0.17% | +0.00% |
| Cash Margin - CCIL | Net Current Assets | 0.02% | — |
| Net Current Assets | Net Current Assets | -0.14% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 12.30 | 16.32 | Low Volatility |
| 3Y | 13.08 | 16.10 | Low Volatility |
| 5Y | 13.02 | 15.67 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.33 | -0.32 | Above Average |
| 3Y | 0.87 | -0.45 | Above Average |
| 5Y | 0.60 | 0.29 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.32 | 0.19 | Above Average |
| 3Y | 2.07 | 1.14 | Above Average |
| 5Y | 1.65 | 0.96 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.87 | 0.96 | Good Risk Adjusted Returns |
| 3Y | 0.89 | 0.96 | Good Risk Adjusted Returns |
| 5Y | 0.91 | 0.94 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From Nippon Life India Asset Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Direct Plan · Growth Option
|
+61.78% | +49.40% | — | +24.96% |
|
Nippon India Silver ETF
Direct Plan
|
+26.05% | +36.23% | — | +25.08% |
|
Nippon India Silver ETF FOF
Direct Plan · IDCW Option
|
+24.99% | +35.38% | — | +24.09% |
|
Nippon India Nifty Pharma ETF
Direct Plan
|
+22.83% | +22.93% | +15.06% | +13.35% |
|
Nippon India Japan Equity Fund
Direct Plan · IDCW Option
|
+20.27% | +21.27% | +9.63% | +9.56% |
|
Nippon India ETF Gold BeES
Direct Plan
|
+16.58% | +30.82% | +23.10% | +15.30% |
|
Nippon India Gold Savings Fund
Direct Plan · Growth Option
|
+16.51% | +30.76% | +22.97% | +10.34% |
|
Nippon India US Equity Opportunities Fund
Direct Plan · IDCW Option
|
+11.90% | +18.73% | +10.93% | +14.93% |
|
Nippon India Fixed Maturity Plan - XLV - Series 5
Direct Plan · Growth Option
|
+7.36% | +8.43% | — | +8.54% |
|
Nippon India Credit Risk Fund (Existing Number of Segregated Portfolios - 1)
Regular Plan · Institutional Plan-Growth Option
|
+7.34% | +8.29% | +7.32% | +7.21% |
About This Scheme
Investment Objective
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
Equity and Equity related Instruments of companies in Pharma Sector – 80%-100%, Equity and Equity Related securities of companies other than those engaged in pharma sector - 0% - 20%, Debt Securities & Money Market instruments - 0% - 20%, & Units issued by REITs and InvITs – 0%-10%
Exit Load
1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.
Fund Managers
Sailesh Raj Bhan
Primary
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.